Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company researching a new class of glycobiology-based therapies for a broad range of diseases, today announced that it has completed enrolling patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate.

18 Jan 2013

Research unveils key gaps in continuity of care for sickle cell patients

Research unveiling key gaps in continuity of care for sickle cell patients transitioning from pediatric to adult care will be presented this week during the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012

Patients with sickle cell disease rely more on emergency room

Patients with sickle cell disease rely more on the emergency room as they move from pediatric to adult health care, according to researchers at Washington University School of Medicine in St. Louis.

10 Dec 2012

Sickle cell disease trial completes phase 3 patient enrollment

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced the completion of patient enrollment for its phase 3 clinical trial to study L-glutamine as a treatment for sickle cell disease.

5 Dec 2012

ADVENTRX Pharmaceuticals updates corporate website

ADVENTRX Pharmaceuticals, Inc. today announced the launch of its redesigned and updated corporate website,www.adventrx.com. The new website features clinician videos, patient resources, and important news pertaining to sickle cell disease and ADVENTRX's lead product candidate, ANX-188 (purified poloxamer 188).

3 Dec 2012

CINJ experts available to comment on importance and uses of blood donations

Every two seconds, someone in the United States is in need of blood. According to the American Red Cross, more than 44,000 blood donations are needed each day. With just one donation of a pint of blood, up to three lives can be saved. Nationally, less than 38 percent of the population is eligible to give blood. In New Jersey, according to the state Department of Health fewer than four percent of eligible residents donate regularly, resulting in the critical need for blood donations.

30 Nov 2012

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its selective histone deacetylase (HDAC) inhibitors will be featured in five posters and one oral presentation at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place December 8-11, 2012, in Atlanta, Georgia.

21 Nov 2012

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

Sickle cell disease is a devastating hereditary condition that affects millions of people, particularly those in West and Central Africa as well as people of African descent in the United States, Europe and South America.

23 Oct 2012

Researchers identify painful symptoms of sickle cell disease

Researchers at Drexel University have identified the physical forces in red blood cells and blood vessels underlying the painful symptoms of sickle cell disease.

18 Oct 2012

Study demonstrates efficacy of genotyping technology in identifying source of clinic infection outbreak

Researchers from East Carolina University used a new technique of genotyping to identify the source of a hematology clinic outbreak of Mycobacterium mucogenicum, a gram-positive, acid-fast bacteria found in tap water. This is the first outbreak of M. mucogenicum in an ambulatory care setting; five other outbreaks have been reported in hospital settings since 1995.

6 Oct 2012

Haploidentical bone marrow transplants for sickle cell disease: an interview with Dr. Javier Bolaños Meade

Bone marrow transplant (also called stem cell transplant) is a medical intervention that allows a physician to deliver very high doses of chemotherapy (if needed) but more importantly, deliver a new immune system to the patient to fight a disease (such as cancer).

3 Oct 2012

Wheeze predicts sickle cell disease crisis

Wheezing is a significant indicator for morbidity in patients with sickle cell disease, US researchers believe.

26 Sep 2012

New clinical trial to evaluate DEX-M74 against hereditary inclusion body myopathy

Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.

25 Sep 2012

Bone marrow transplants hold promise for sickle cell patients

Research shows that even partially matched bone marrow transplants are able to eliminate sickle cell disease in some patients with sickle cell anemia.

24 Sep 2012

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms and the need for a lifetime of pain medications and blood transfusions.

24 Sep 2012

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially-matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms, and the need for a lifetime of pain medications and blood transfusions. The researchers say the use of such marrow could potentially help make bone marrow transplants accessible to a majority of sickle cell patients who need them.

21 Sep 2012

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

21 Sep 2012

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Gamida Cell, a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company's second pipeline product.

20 Sep 2012

Emmaus Medical to complete target enrollment in L-Glutamine Phase III trial for sickle cell disease

In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.

14 Sep 2012

Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

Research unveils key gaps in continuity of care for sickle cell patients

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Patients with sickle cell disease rely more on emergency room

Sickle cell disease trial completes phase 3 patient enrollment

ADVENTRX Pharmaceuticals updates corporate website

CINJ experts available to comment on importance and uses of blood donations

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

Researchers identify painful symptoms of sickle cell disease

Study demonstrates efficacy of genotyping technology in identifying source of clinic infection outbreak

Haploidentical bone marrow transplants for sickle cell disease: an interview with Dr. Javier Bolaños Meade

Wheeze predicts sickle cell disease crisis

New clinical trial to evaluate DEX-M74 against hereditary inclusion body myopathy

Bone marrow transplants hold promise for sickle cell patients

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Emmaus Medical to complete target enrollment in L-Glutamine Phase III trial for sickle cell disease

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in